Two Top Stories of NYSE: Ceragon Networks Ltd. (NASDAQ:CRNT), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Ceragon Networks Ltd. (NASDAQ:CRNT)

The shares of Ceragon Networks Ltd. (NASDAQ:CRNT) started off the last trading session with the price of $2.67 while closing the day with the price of $2.65. The shares of Ceragon Networks Ltd. (NASDAQ:CRNT) Rise 0% with the Loss of -0.02 points.

The shares of Ceragon Networks Ltd. (NASDAQ:CRNT) traded with the day volume of 1.12 Million shares whereas its average trading volume is 643.56 Million.

While analyzing the past performance of the stock we can see that the shares of Ceragon Networks Ltd. (NASDAQ:CRNT) Loss -3.64% in the last week while rising 22.12% in the last month. Past quarter performance shows the green light with 22.69%. The semi-annual and annual performance shows 26.79% and -23.41% respectively.

Some critical values of the shares of Ceragon Networks Ltd. (NASDAQ:CRNT) to be discussed here are: the beta which shows the value at 0.61 while Average True Range of Ceragon Networks Ltd. (NASDAQ:CRNT) demonstrate the value at 0.17. The weekly and monthly volatility of the shares of Ceragon Networks Ltd. (NASDAQ:CRNT) are indicated at 4.64% and 7.55%. Also to discuss here is the Relative Strength Index or RSI which is depicted at 52.51.

While studying the financial position of the shares of Ceragon Networks Ltd. (NASDAQ:CRNT), we can see that the Market capitalization of the company is at 212 Million. The shares outstanding for the company is 80 Million and the shares float stands at 55.89 Million. The income of the company stand at 15.6 Million while the sales stand at 332 Million.

Here are some critical ratios for a financial perspective: Earnings Per Share or EPS of the company stand at 0.2, Price to Earnings or P/E is at 13.59, Price to Sales P/S show the value of 0.64, the Return on Asset ROA stood at 0.06 and the Return on Equity ROE depicted at 0.124 while Return on Investment ROI is at 0.16.


Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) started its previous trading session at $346 and closed at $344.55 showing a Rise of 0.83 Percent.

The Company traded with an average Volume of 901.97 Million whereas, its Day Volume stood at 1.23 Million.

Looking at the performance of the stock, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Gain 3.19% in the last week in its shares price and 6.8% in the last month. Quarterly performance shows a red of -7.78 Percent while Semi-Annual and Annual performances shows a -26.92 and -11.25 percent respectively.

Beta for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands at 1.55 while the ATR (average true range) is at 11.1. The Stock’s Weekly and Monthly Volatility is 2.31% and 3.16% respectively showing a RSI value of 56.7.

While studying the financial position of the shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), we can see that the Market capitalization of the company is at 36.92 Billion. The shares outstanding for the company is 107.15 Million and the shares float stands at 79.02 Million.

The Company generated an income of 1.52 Billion and the sales of 5.87 Billion in the Trailing Twelve Months period.

While analyzing the stock from technical aspects, Diluted Earnings per share stands at $13.14 a share. P/E (price to earnings) and P/S (price to sales) values are 26.23 and 6.29 respectively.

The Return on Assets stands at 0.144, ROE shows a value of 0.212 and ROI for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is 0.223 as of Trailing Twelve Months period.

The following two tabs change content below.

Eldred Matthew

Eldred Matthew covers Healthcare Sector Company recent Press Releases news updates. He has three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

View all contributions by

Eldred Matthew covers Healthcare Sector Company recent Press Releases news updates. He has three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Comment